Hearing Evaluation in People Aged 50 to 85 With Early Alzheimers and Parkinsons Diseases Compared to Healthy Adults

What this Trial Is About

Researchers are studying hearing characteristics in people aged 50 to 85 with early-stage neurodegenerative disorders, including Alzheimers and Parkinsons disease. The study focuses especially on those who have trouble understanding speech in noisy environments despite normal hearing tests, known as hidden hearing loss. The goal is to explore how common various hearing problems are in these patients compared to healthy individuals and to identify possible related biomarkers. Participants undergo a wide range of hearing tests such as tonal and vocal audiometry in silence and noise, distortion product otoacoustic emissions, middle ear muscle reflex, auditory brainstem response, and electrocochleography. These tests are combined with disease-related data and blood marker analysis. Study groups include healthy controls, patients with amnestic mild cognitive impairment, and patients with Parkinsons disease. During the study, participants will have hearing assessments and provide health information and blood samples. Researchers measure the prevalence and degree of hidden and sensorineural hearing loss within one month of enrollment. The study involves no randomization or blinding. Participants are monitored for up to one month after inclusion, and safety and hearing function are carefully evaluated. The entire participation period is relatively short, focusing on detailed hearing phenotyping and associated biomarkers.

Early Stage of Alzheimer's and Parkinson's Diseases, HearIng Relevance (SAPHIR)